Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02511886 · ClinicalTrials.gov registry record · Phase 2
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
A Phase 2 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02511886 is a Phase 2 study that has completed, run by Indivior. The registered enrollment target is 18 participants.
The verdict
NCT02511886, a Phase 2 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study will determine the maximum tolerated dose (MTD) of arbaclofen placarbil (AP) in the treatment of subjects with Alcohol Use Disorder (AUD). For every two subjects receiving AP, one subject will receive placebo.
Interventions
- DRUG Placebo
- DRUG Arbaclofen Placarbil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02511886
The ClinicalTrials.gov registry entry for NCT02511886 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02511886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02511886 about?
NCT02511886 is a clinical study titled "A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder". This study will determine the maximum tolerated dose (MTD) of arbaclofen placarbil (AP) in the treatment of subjects with Alcohol Use Disorder (AUD). For every two subjects receiving AP, one subject will receive placebo.
What is the current status of trial NCT02511886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2015-09. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02511886?
The interventions under investigation include: Placebo (DRUG), Arbaclofen Placarbil (DRUG).
Who is sponsoring clinical trial NCT02511886?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.